EMJ GOLD - European Medical Journal

Continue

Pharma News, Views & Analysis

Filter Advertise With Us

Pfizer joins GSK in RSV success

Pfizer plans to file for approval for its RSV vaccine for infants by the end of 2022 after achieving positive Phase 3 results.

First RSV vaccine for older adults earns pivotal Phase 3 results

A first-in-class vaccine for respiratory syncytial virus has shown to be highly efficacious in a Phase III trial, GSK has announced.

Promising outlook for integrating young talent in pharma

Collaboration between the pharmaceutical industry and academia is on the rise, according to a recent survey from the ABPI.

Pfizer-BioNTech assemble with the Avengers in COVID booster drive

Pfizer and BioNTech collaborate with Marvel on a comic encouraging COVID-19 booster vaccinations in the US.

Moderna joins BIA as 500th member

Moderna has joined the UK’s BioIndustry Association (BIA), taking the trade association’s membership to over 500 companies.

GSK and Microsoft tackle Nepal disease transmission

A new disease surveillance project to curb the spread of known and unknown pathogens, especially mosquito-borne illnesses, has been launched by GSK and Microsoft in Nepal.

First malaria vaccine granted WHO prequalification

The World Health Organization (WHO) has granted the first prequalification for a malaria vaccine to GSK’s Mosquirix in an important step toward immunising children against the disease.

Access win for HIV patients in sub-Saharan Africa

The injectable HIV treatment cabotegravir is set to become more widely available in sub-Saharan Africa following a new licensing agreement.